Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
木曜日, 9 03

Pfizer Inc

PFENYSE
Trade with Public
Trade with Public
$29.02
0.471.65%
近くで: Sep 2, 5:00 PM EST
$28.99
-0.03-0.1%
時間外: 7:59 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

Pfizer Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pfizer (PFE).

Price Target Range — 12 Quarters

Analyst Consensus — 19 Analysts

7Buy
10Hold
2Sell
Consensus RatingNeutral# Analysts19Avg. Consensus PT$30Upside to Avg. PT+2.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 7, 2026GuggenheimVamil DivanPT CutBuy$35→$31
Jul 13, 2026BMO CapitalEvan David SeigermanPT CutOutperform$34→$30
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
CNBC Halftime Report Final Trades: Pfizer, Nvidia, Take-Two Interactive Software, Cheniere Energy

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.
Avi Kapoor

PRO
Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $31

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target from $35 to $31.
Benzinga Newsdesk

Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenue at $14.39B. Stock rose 0.1% on Monday.
Avi Kapoor

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.
Vandana Singh

PRO
BMO Capital Maintains Outperform on Pfizer, Lowers Price Target to $30

BMO Capital analyst Evan David Seigerman maintains Pfizer (NYSE:PFE) with a Outperform and lowers the price target from $34 to $30.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved